Antidepressant “Black Box” Warning For Pediatric Suicidality Risk Recommended
This article was originally published in The Pink Sheet Daily
Executive Summary
“Black box” warning would encourage discussion of risks and benefits of antidepressant therapy in children by physicians, FDA advisory committee members say. Warning likely to affect direct-to-consumer advertising, FDA notes. Committee members recommend class warning for all antidepressants, including new products.